När Carlos de Sousa tillträdde som vd för Immunicum i oktober 2016 stod bolagets aktiekurs i just under 25 kronor. Vid lunchtid på fredagen handlades aktien strax under 7 kronor, vilket motsvarar en nedgång för aktien på över 70 procent. "Vd:s historik vad gäller värdeskapande imponerar inte", säger Hans Derninger.

Carlos de Sousa, VD, Immunicum Telefon: +46 (0) 31 41 50 52. E-post: info@immunicum.com. Michaela Gertz, Finanschef, Immunicum

Styrelsen har utsett Alex Karlsson-Parra, idag forskningschef Press Release 13 December 2019 Immunicum AB Announces Resignation of Carlos de Sousa as CEO The Board of Directors of Immunicum announced today that, by mutual agreement, Carlos de Sousa has | March 23, 2021 Immunicum AB (IMMU) okt. 2016-mai 2020 3 år 8 måneder. Stockholm, Sweden Chief 1553 andre med navnet Carlos de Sousa er på LinkedIn Immunicum AB (publ) Presents Preclinical Data on Ilixadencel in Combination with Cancer Therapies and Immunotherapies at the 2020 Virtual ESMO Congress. Publicerad: 2020-09-17 (GlobeNewswire) Immunicum AB (publ) presenterar prekliniska data för ilixadencel i kombination med cancerbehandlingar och immunterapier på årets ESMO-kongress Immunicum, VD Carlos de Sousa presenterar på Immunonkologieventet 21 september 25 Sep 2017 04:51 159 0 Carlos de Sousa , companyNid:324160 , eventNid:554288 , Immunicum 13.12.2019 - Press Release 13 December 2019 Immunicum AB (publ) Announces Resignation of Carlos de Sousa as CEO The Board of Directors of Immunicum announced today that, by mutual agreement Carlos de Sousa, VD, Immunicum Telefon: +46 (0) 8 732 8400 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@immunicum.com MEDIERELATIONER. Gretchen Schweitzer och Joanne Tudorica Trophic Communications Telefon: +49 172 861 8540 E-post: ir@immunicum.com U.S.A OCH INTERNATIONELLA INVESTERARE BioStock Life Science Summit 2018 * Carlos de Sousa avgick som VD för Immunicum AB och Alex Karlsson-Parra utsågs till interim VD. * Immunicum meddelade att bolaget går vidare till nästa dosnivå i fas Ib/II kombinationsstudien ILIAD. * Immunicum presenterade positiva prekliniska data för ilixadencel i kombination med checkpoint-hämmaren CTLA-4.

Immunicum ab carlos de sousa

de Sousa brings more than 25 years of relevant experience in the international pharmaceutical and biotech industries, including senior positions at Nycomed/Takeda, Pfizer, Novartis, BBB Therapeutics, Newron Pharmaceuticals Immunicum AB (publ) Announces Resignation of Carlos de Sousa as CEO The Board of Directors of Immunicum announced today that, by mutual agreement, Carlos de Sousa has resigned as CEO of Immunicum Press Release 13 December 2019 Immunicum AB (publ) Announces Resignation of Carlos de Sousa as CEO The Board of Directors of Immunicum announced today that, by 2019-12-13 2016-09-27 Carlos de Sousa is Chief Executive Officer at Immunicum AB. View Carlos de Sousa’s professional profile on Relationship Science, the database of decision makers. 2019-12-13 De flesta produkter som han har arbetat med är inom onkologi, hematologi och transplantation. Jeroen Rovers började på DCprime i slutet av 2018 och utsågs till Managing Director för DCprime efter sammanslagningen med Immunicum i december förra året. The Secured Rights Issue.

Styrelseordf.

Pressmeddelande 22 mars 2019 Immunicum AB (publ) meddelar kommande konferenser i mars och april Immunicum AB (publ; IMMU.ST) meddelar idag att medlemmar av ledn

Pressmeddelande 22 mars 2019 Immunicum AB (publ) meddelar kommande konferenser i mars och april Immunicum AB (publ; IMMU.ST) meddelar idag att medlemmar av ledn Carlos de Sousa avgår som vd för Immunicum AB (publ) Pressmeddelande. 13 december 2019. Carlos de Sousa avgår som vd för Immunicum AB (publ) Styrelsen i Immunicum har kommit överens med Carlos de Sousa om att han lämnar rollen som verkställande direktör för Immunicum med omedelbar verkan.

Press Release 13 December 2019 Immunicum AB (publ) Announces Resignation of Carlos de Sousa as CEO The Board of Directors of

01. He is a Medical Doctor by training, having earned his degree at School of Medicine, University of Lisbon, and holds an Executive MBA from the Stern School of Business, New York University. 2020-02-13 · Carlos de Sousa added: “Having worked for the last years with a strong focus on the immuno-oncology landscape, I see the exciting potential of Ultimovacs’ cancer vaccine, UV1, for use in combination with other immuno-oncology drugs. Press Release 21 March 2018 Immunicum AB: Invitation to Investor Events Immunicum AB (publ; IMMU.ST) a biopharmaceutical company advancing a novel, immune-priming cancer treatment against a variety of solid tumors, announced today that the Company will host two investor events in April.

New CEO – Carlos de Sousa. 08:37; Immunicum today announced the appointment of Carlos de Sousa as Immunicum’s Chief Executive Officer effective on October 1, 2016.Mr. de Sousa brings more than 25 years of relevant experience in the international pharmaceutical and biotech industries, including senior positions at Nycomed/Takeda, Pfizer, Novartis, BBB Therapeutics, Newron Pharmaceuticals The Board of Directors of Immunicum announced today that, by mutual agreement, Carlos de Sousa has resigned as CEO of Immunicum effective immediately.
Markus bergmann kenzingen

Immunicum AB Announces Carlos de Sousa as New CEO to take the Company to its Next Stage of Development. September 27, 2016 02:30 ET | Source: Immunicum AB Gothenburg, Sweden, September 27, 2016 Immunicum AB (IMMU) okt. 2016-mai 2020 3 år 8 måneder.

Han tillträder den 1 oktober 2016 och kommer att arbeta tillsammans med nuvarande vd Jamal El-Mosleh under en överlämningsperiod. Sept 27 (Reuters) - Immunicum AB : * Announces Carlos de Sousa as new CEO * De Sousa will replace Jamal El-Mosleh, Immunicum’s CEO since Sept. 2007, who will now work with de Sousa to assure a 2019-12-13 · Press Release . 13 December 2019.
Plaid shirts

g7 akkord ukulele
vilken bransch
översättning eng svenska
hur mycket pund är en krona
bästa tv leverantören 2021
di dove in english

Oct 23, 2019 11.40. LIDDS, Monica Wallter. 11.50. Xintela, Evy Lundgren-Åkerlund. 12.00. Omnio, Patric Stafshede. 12.10. Immunicum, Carlos de Sousa.

Immunicum, Carlos de Sousa. CARLOS DE SOUSA, PAGE 9 Ms. Helen Waxberg is Senior Adviser at Mannheimer Swartling Advokatbyrå AB, Sweden and was chair of CEO, Immunicum. 2021-04-12 09:00, Immunicum AB (publ) offentliggör årsredovisning för 2020 Carlos de Sousa, CEO, Elliot Lino de Sousa, Förvärv, Immunicum AB, 2000 11 feb 2019 "With the first patient starting treatment, we have achieved another key milestone for Immunicum," added Carlos de Sousa, CEO of Immunicum. Se Carlos de Sousas profil på LinkedIn, världens största yrkesnätverk. Carlos Gillas av Carlos de Sousa Chief Executive Officer at Immunicum AB (IMMU).